View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 12, 2018

LabCorp’s Covance forms new biologic drug development unit

US-based life sciences company LabCorp’s Covance Drug Development business has formed an immunology and immunotoxicology (I&I) unit aimed at global biologic drug development needs.

US-based life sciences company LabCorp’s Covance Drug Development business has formed an immunology and immunotoxicology (I&I) unit aimed at global biologic drug development needs.

The new unit will combine Covance’s expertise in flow cytometry, immunoassays and cell-based assay operations with scientific expertise in immunotoxicology study design, direction and operation.

Covance expects that this integration will provide a more comprehensive offering for large-molecule drugs.

Covance CEO John Ratliff said: “With the formation of this team, we continue to demonstrate Covance’s commitment to strengthening our biologics solutions with key investments in scientific staff, technology and facilities.

“Integrating our scientific and operational know-how into a seamless group allows us to deliver even richer scientific insights and faster cycle times for clients’ biologic programmes, which helps our clients bring cutting-edge new drugs to patients faster.”

“Our growing I&I team is capitalising on the global experience of our established facilities in the US, Germany and the UK to deliver comprehensive support for large-molecule development.”

Covance offers support and advice on various stages of biologics development such as pre-clinical assessment, regulatory submission and clinical sample analysis.

Through the new unit, the company will also provide access to bioanalysis to be used in regulatory submission, and to Phase I clinical research units for first-in-human and first-in-patient studies.

The I&I experts at the unit will benefit from the expertise of Covance’s clinical development and commercialisation, translational biomarker and immuno-oncology teams, and LabCorp’s scientific and technical capabilities.

According to senior vice-president of Covance Early Development, Steve Street, the unit will also work on new assay development and validation.

Street added: “Our growing I&I team is capitalising on the global experience of our established facilities in the US, Germany and the UK to deliver comprehensive support for large-molecule development, from innovative testing methods to insightful data analysis and interpretation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU